Guggenheim Maintains Buy on Hims & Hers Health, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Jack Wallace has maintained a Buy rating on Hims & Hers Health (HIMS) and increased the price target from $15 to $17.
February 27, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Jack Wallace reaffirmed a Buy rating on Hims & Hers Health and raised the price target from $15 to $17.
The increase in the price target by a reputable analyst suggests a positive outlook on the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100